Evidence map›Paper›PMID 36745238›Full record

ArticleJournal of gastroenterology2023

Organoids transplantation as a new modality to design epithelial signature to create a membrane-protective sulfomucin-enriched segment.

Satoshi Watanabe, Nobuhiko Ogasawara, Sakurako Kobayashi, Sakura Kirino, Masami Inoue, Yui Hiraguri, Sayaka Nagata, Hiromichi Shimizu, Go Ito, Tomohiro Mizutani and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Satoshi Watanabe *Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo, 113-8510, Japan.
Nobuhiko Ogasawara *Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo, 113-8510, Japan.
Sakurako KobayashiDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo, 113-8510, Japan.
Sakura KirinoDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo, 113-8510, Japan.
Masami InoueDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo, 113-8510, Japan.
Yui HiraguriDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo, 113-8510, Japan.
Sayaka NagataDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo, 113-8510, Japan.
Hiromichi ShimizuCenter for Stem Cell and Regenerative Medicine, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo, 113-8510, Japan.
Go ItoAdvanced Research Institute, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo, 113-8510, Japan.
Tomohiro MizutaniDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo, 113-8510, Japan.
Yasuhiro NemotoDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo, 113-8510, Japan.
Kiichiro TsuchiyaDepartment of Gastroenterology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennoudai, TsukubaTsukuba, Ibaraki, 305-8575, Japan.
Ryuichi OkamotoDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo, 113-8510, Japan.
Mamoru WatanabeAdvanced Research Institute, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo, 113-8510, Japan.
Shiro YuiCenter for Stem Cell and Regenerative Medicine, Tokyo Medical and Dental University (TMDU), Bunkyo-ku, Tokyo, 113-8510, Japan. yui.arm@tmd.ac.jp.ORCID 0000-0003-4268-647X
Tokyo Medical and Dental University · JPUniversity of Tsukuba · JP

Funding

Japan Agency for Medical Research and Development (AMED) 20bk0104008h0003Japan Agency for Medical Research and Development (AMED) 20bm0304001h0008Japan Agency for Medical Research and Development (AMED) 20bm0404055h0002Japan Agency for Medical Research and Development (AMED) 20bm0704029h0003Japan Science and Technology Agency (JST) Forrest Program JPMJFR2012MEXT/JSPS KAKENHI 18K15743MEXT/JSPS KAKENHI 19H01050MEXT/JSPS KAKENHI 19H03634MEXT/JSPS KAKENHI 20H03657MEXT/JSPS KAKENHI 22H00472
6 · The paper itself

Abstract

backgroundThe organoids therapy for ulcerative colitis (UC) is under development. It is important to dissect how the engrafted epithelium can provide benefits for overcoming the vulnerability to inflammation. We mainly focused on the deliverability of sulfomucin, which is reported to play an important role in epithelial function.

methodsWe analyzed each segment of colon epithelium to determine differences in sulfomucin production in both mice and human. Subsequently, we transplanted organoids established from sulfomucin-enriched region into the injured recipient epithelium following dextran sulfate sodium-induced colitis and analyzed the engrafted epithelium in mouse model.

resultsIn human normal colon, sulfomucin production was increased in proximal colon, whereas it was decreased in the inflammatory region of UC. In murine colon epithelium, increased sulfomucin production was found in cecum compared to distal small intestine and proximal colon. RNA sequencing analysis revealed that several key genes associated with sulfomucin production such as Papss2 and Slc26a1 were enriched in isolated murine cecum crypts. Then we established murine cecum organoids and transplanted them into the injured epithelium of distal colon. Although the expression of sulfomucin was temporally decreased in cecum organoids, its secretion was restored again in the engrafted patches after transplantation. Finally, we verified a part of mechanisms controlling sulfomucin production in human samples.

conclusionThis study illustrated the deliverability of sulfomucin in the disease-relevant grafting model to design sulfomucin-producing epithelial units in severely injured distal colon. The current study is the basis for the better promotion of organoids transplantation therapy for refractory UC.

Indexed as

ColitisColitis, UlcerativeAnimalsColonDextran SulfateDisease Models, AnimalHumansIntestinal MucosaMiceMucinsOrganoidsDextran SulfateMucinssulfomucinEpithelial designOrganoids transplantationUlcerative colitis

Identifiers

PMID36745238
OpenAlexW4319295152

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.